Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3
Main Article Content
Keywords
Tralokinumab, Atopic dermatitis, Human monoclonal antibody, Interleukin, Efficacy, Safety profile
Abstract
Background: Tralokinumab, a monoclonal antibody that specifically neutralizes interleukin (IL)-13, is approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). Tralokinumab was studied in ECZTRA3 (NCT03363854), a randomized, double-blind, multi-national, placebo-controlled Phase 3 trial of tralokinumab in adults with moderate-to-severe AD.
Objective: We conducted a post-hoc analysis in the United States (US) subset of ECZTRA3 patients to inform healthcare practitioners and payers on the efficacy and safety of tralokinumab in the US setting.
Methods: Patients were treated with either 300 mg tralokinumab (n=63) or placebo (n=25) every 2 weeks (Q2W) in combination with TCS as needed for an initial 16 weeks. Thereafter, tralokinumab-treated patients continued with either Q2W dosing or Q4W+TCS for 16 additional weeks. Primary, secondary, and safety endpoints of the ECZTRA3 US subset were evaluated at 16 and 32 weeks following main statistical analyses (previously published).
Results: At Week 16, 37.1% tralokinumab+TCS vs 12.0% placebo+TCS reached Investigator’s Global Assessment (IGA) 0/1 (nominal P=0.039); 56.5% of tralokinumab+TCS vs 24.0% placebo+TCS (nominal P=0.012) achieved the Eczema Area and Severity Index (EASI)-75. Secondary, patient-reported outcomes including itch score and health-related quality of life (HRQoL) were also improved at Week 16 versus baseline, more so for tralokinumab+TCS group. Tralokinumab was well tolerated, with an overall safety profile comparable to placebo.
Conclusions: Consistent with the full ECZTRA3 population, US patients with moderate-to-severe AD treated with tralokinumab+TCS as needed achieved greater symptom relief, reductions in disease severity and improvement of HRQoL than placebo+TCS, with comparable safety.
References
2. Beasley R, of Asthma TIS. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The Lancet. 1998;351(9111):1225-1232.
3. Lee BW, Detzel PR. Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries. Annals of Nutrition and Metabolism. 2015;66(suppl 1)(Suppl. 1):18-24. doi:10.1159/000370221
4. Garrett JPD, Hoffstad O, Apter AJ, Margolis DJ. Racial comparison of filaggrin null mutations in asthmatic patients with atopic dermatitis in a US population. Journal of Allergy and Clinical Immunology. 2013/11/01/ 2013;132(5):1232-1234. doi:https://doi.org/10.1016/j.jaci.2013.07.005
5. Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics. 2006/04/01 2006;38(4):441-446. doi:10.1038/ng1767
6. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. Jan 2020;75(1):54-62. doi:10.1111/all.13954
7. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. Dec 2014;71(6):1218-33. doi:10.1016/j.jaad.2014.08.038
8. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. Jun 2018;32(6):850-878. doi:10.1111/jdv.14888
9. U.S. Food and Drug Administration. ADBRY™ (tralokinumab-ldrm) injection, for subcutaneous use. Accessed 12 July, 2022. https://mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net/-/media/corporatecommunications/us/therapeutic-expertise/our-product/adbrypi.pdf?rev=65a4030a7140473198c24e795b9c19f1
10. Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. Mar 2021;184(3):450-463. doi:10.1111/bjd.19573
11. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol. Mar 2019;139(3):583-590. doi:10.1016/j.jid.2018.08.028
12. Yu B, Gastwirth JL. A method of assessing the sensitivity of the Cochran-Mantel-Haenszel test to an unobserved confounder. Philos Trans A Math Phys Eng Sci. Jul 13 2008;366(1874):2377-88. doi:10.1098/rsta.2008.0030
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.